Blood Cancer Patients (Kahler’s Disease) Treatment with Palmitoylethanolamide

Blood Cancer Patients (Kahler’s Disease) Treatment with Palmitoylethanolamide

What Is Kahler’s Disease?

Kahler’s disease, or multiple myeloma, is a type of blood cancer from which patients usually die within 3-4 years. It is possible to treat this type of cancer with chemotherapy, specifically with the substances bortezomib and thalidomide. However, these substances are quite damaging to the nerves and can cause severe pain and function disorders. If this is the case, treatment cannot be continued and the patient has an increased risk of death.

How Does Palmitoylethanolamide Help with Kahler’s Disease?

Luckily, a new treatment became available. Patients with this type of blood cancer can take palmitoylethanolamide during their treatment with bortezomib and thalidomide to decrease pain and protect the nerves against further damage. The pain decreases and nerve function increases, so treatment with anti-cancer substances can continue. Palmitoylethanolamide can be found in capsules, but also recently as a liposomal product which greatly increases bioavailability.

Aside from reducing pain, PEA also protects the nerves against damage from chemotherapy: less pain and better nerve function.

After completing their study on 20 Kahler’s disease patients as mentioned below, the authors concluded that palmitoylethanolamide, a natural bodily compound, is a safe substance to offer patients with Kahler disease blood cancer and that the painful neuropathy decreases whereas the nerve function improves. All this while chemotherapy can continue.

Moreover, even before this study, the positive effects of palmitoylethanolamide against pain and inflammation, as well as its complete safety have been documented well through more than 400 scientific studies conducted over more than 60 years.

In a severe condition such as painful neuropathy associated with multiple myeloma and chemotherapy, a safe substance such as PEA provides significant restoration of nerve function. [1]

In case of a type of cancer like Kahler, palmitoylethanolamide can not only decrease the side effects of chemotherapy, but also protect the nerves so oncologists can continue treatment with cancer-killing substances longer than usual. This means there’s an increased chance of survival.

39 clinical studies have been conducted in which it showed that palmitoylethanolamide, a supplement available in the United States as PEA, is an effective pain reliever as well as an anti-inflammatory agent. Now it seems like it can also be beneficial to cancer patients.

 

Reference

[1] Truini A, Biasiotta A, Di Stefano G, La Cesa S, Leone C, Cartoni C, Federico V, Petrucci MT, Cruccu G. | Palmitoylethanolamide restores myelinated-fibre function in patients with chemotherapy-induced painful neuropathy. | CNS Neurol Disord Drug Targets. | 2011 Dec;10(8):916-20.